GDC-0834 (Genentech, San Francisco, CA, USA) is a highly potent, selective, reversible adenosine triphosphate (ATP)-competitive BTK inhibitor developed as a potential drug for treating RA and other immune and inflammatory diseases [77]. This evidence concerns the gene BTK and rheumatoid arthritis.